Avenna

Executive Summary

Avenna is a Cambridge, UK-based biotechnology company pioneering precision medicine for chronic inflammatory diseases (CIDs) through glycomic diagnostics. Founded in 2021, the company translates cutting-edge glycomic research into affordable, blood-based biomarker tests that enable early detection and personalized treatment of conditions like inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). By focusing on prognostic and predictive biomarkers, Avenna aims to shift the paradigm from reactive disease management to proactive, individualized care, potentially improving patient outcomes while reducing healthcare costs. The company's platform addresses a significant unmet need in CID diagnostics, where current tools often fail to predict disease progression or treatment response. Avenna's approach leverages the underutilized glycome—the complete set of glycans in an individual—to capture disease-specific signatures that conventional genomics or proteomics may miss. This could unlock a new class of diagnostic tests with higher accuracy and earlier actionable insights. With the global CID diagnostics market projected to grow substantially, Avenna is well-positioned to capture value if it successfully validates its technology in clinical studies. However, as a private, early-stage company, its path to commercialization depends on securing funding, completing clinical validation, and forging strategic partnerships. The next 12–18 months will be critical for demonstrating proof-of-concept and attracting investment.

Upcoming Catalysts (preview)

• Q3 2026Series A financing round70% success
• Q4 2026Publication or presentation of proof-of-concept clinical data for IBD biomarker60% success
• H1 2027Strategic collaboration with a pharmaceutical or diagnostic company50% success